A Phase 3 interventional study of 17-beta estradiol and 17-beta estradiol in Genetic Disorder and Turner Syndrome, sponsored by Novo Nordisk A/S. Completed at 28 sites in Spain. Open to female participants. Per ClinicalTrials.gov, last updated 2017-02-28.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Turner Syndrome by Novo Nordisk A/S — none open to participants now, 2 under way, 2 of them phase 3. Turner Syndrome · Novo Nordisk A/S.
Among the 12 studies in Turner Syndrome by Novo Nordisk A/S, this one is the only one that started in 1998, is one of 5 in phase 3, and was the 9th registered.
125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.
Browse Turner Syndrome studies →None of the 12 studies in Turner Syndrome by Novo Nordisk A/S is open now. The open studies under Turner Syndrome, anywhere →
Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 1987; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 67 across 52 interventional studies indexed under Turner Syndrome.
Median enrollment 61 across the 8 interventional studies, 3,729 across the 4 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Turner Syndrome by Novo Nordisk A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe. The aim of the trial is to induce normal pubertal development in girls with Turner Syndrome in accordance with that of their peers and their individual state psychosocial maturation.
125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.
This study's enrollment of 50 is below the median of 67 across 52 interventional studies indexed under Turner Syndrome.
Browse Turner Syndrome studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Turner Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 17-beta estradiol
Drug: 17-beta estradiol
5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
Pubertal stage assesed by Tanner score
FSH (Follicle Stimulating Hormone) levels
Height velocity
Pubertal stage assessed by Tanner score: Breast, pubic hair, axillary hair
Adverse events
Ran from Jul 1998 to primary completion in Jul 2004, 72 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol